Related references
Note: Only part of the references are listed.Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition
Gali Soria et al.
BMC CANCER (2011)
Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age An Analysis of 657 Patients
Laura C. Collins et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Synthetic Lethality -- A New Direction in Cancer-Drug Development.
J. Dirk Iglehart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The inflammatory chemokines CCL2 and CCL5 in breast cancer
Gali Soria et al.
CANCER LETTERS (2008)
Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion
Georg Sauer et al.
CLINICAL CANCER RESEARCH (2008)
Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: A basis for tumor-promoting interactions
Gali Soria et al.
CYTOKINE (2008)
What is triple-negative breast cancer?
William J. Irvin et al.
EUROPEAN JOURNAL OF CANCER (2008)
Tumor-derived CCL5 does not contribute to breast cancer progression
Mevan M. Jayasinghe et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder
Sami Tsukishiro et al.
GYNECOLOGIC ONCOLOGY (2006)
The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients
Neora Yaal-Hahoshen et al.
CLINICAL CANCER RESEARCH (2006)
Flow Cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of Superficial Transitional cell carcinoma of bladder
A Agarwal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Targeting NF-κB in hematologic malignancies
T Braun et al.
CELL DEATH AND DIFFERENTIATION (2006)
Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival
S Ek et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
GG Vaday et al.
PROSTATE (2006)
Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
P Serafini et al.
SEMINARS IN CANCER BIOLOGY (2006)
CCR5, RANTES and CX3CRl polymorphisms:: Possible genetic links with acute heart rejection
E Simeoni et al.
TRANSPLANTATION (2005)
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection
JW Tyner et al.
NATURE MEDICINE (2005)
Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens
M Gu et al.
ACTA CYTOLOGICA (2005)
Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus
DQ Ye et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2005)
Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon γ-induced RANTES/CC15 expression in macrophages
JG Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi
FS Machado et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Preferential transmission and association of the -403 G→A promoter RANTES polymorphism with atopic asthma
SA Al-Abdulhadi et al.
GENES AND IMMUNITY (2005)
Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays
Y Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-γ-independent mechanisms
XY Shi et al.
JOURNAL OF IMMUNOLOGY (2004)
Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease
EA Danna et al.
CANCER RESEARCH (2004)
Elevated expression of CCL5/RANTES in adult T-cell leukemia cells:: Possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax
N Mori et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis
E Simeoni et al.
EUROPEAN HEART JOURNAL (2004)
Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior
ZY Mi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma
T Kondo et al.
JOURNAL OF UROLOGY (2004)
Molecular profiling of inflammatory breast cancer:: Identification of a poor-prognosis gene expression signature
I Bièche et al.
CLINICAL CANCER RESEARCH (2004)
RANTES: a genetic risk marker for multiple sclerosis
R Gade-Andavolu et al.
MULTIPLE SCLEROSIS JOURNAL (2004)
A dual role for tumor-derived chemokine RANTES (CCL5)
EP Adler et al.
IMMUNOLOGY LETTERS (2003)
CCR5 expression influences the progression of human breast cancer in a p53-dependent manner
S Mañes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Expression of CCL5/rantes by Hodgkin and reed-sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue
M Fischer et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-γ-primed IL-12 production by IFN regulatory factor 1
JG Liu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The RANTES promoter polymorphism: A genetic risk factor for near-fatal asthma in Chinese children
TC Yao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells
A Freund et al.
ONCOGENE (2003)
Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence
M Terabe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma
N Hizawa et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Tumor necrosis factor-α-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells -: Modulation by glucocorticoids and β-agonists
AJ Ammit et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2002)
Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1
GT Kozma et al.
ALLERGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Chemokine receptor desensitization in tumor-bearing mice
RA Kurt et al.
CELLULAR IMMUNOLOGY (2001)
β2-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells
MP Hallsworth et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2000)
The-403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma
AA Fryer et al.
GENES AND IMMUNITY (2000)
Tumor necrosis factor-α-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells -: Modulation by cyclic adenosine monophosphate
AJ Ammit et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2000)
Transcriptional regulation of RANTES expression in T lymphocytes
A Song et al.
IMMUNOLOGICAL REVIEWS (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism
AL Rakhmilevich et al.
CANCER GENE THERAPY (2000)
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ
BA Pulaski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer
Y Li et al.
ONCOGENE (2000)
Resection of solid tumors reverses T cell defects and restores protective immunity
S Salvadori et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
